Primary Biliary Cirrhosis Drugs Market Outlook 2020, Global Demand, Size Estimation, Industry Share, Business Insight, Challenges, Opportunities, Regional Revenue
SEATTLE, March 25, 2021, (PHARMIWEB) — Primary biliary cirrhosis (PBC) also called primary biliary cholangitis is an autoimmune disease of liver, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. PBC causes autoimmunity, infection and/or genetic predisposition. The primary symptoms of primary biliary cirrhosis are itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1539
PBS develops over the time and eventually causes the liver to stop working completely in later stages. Most people are diagnosed early, before the disease progresses. Delay in treatment of cirrhosis can cause liver failure and a liver transplant is necessary for survival. Diagnostic tests for primary biliary cirrhosis includes examination of elevated levels of IgM immunoglobulin levels, lipids, cholesterol and bilirubin, liver biopsy, ultrasonography, CT scanning or MRI. Increasing research and development activities and rising incidence of primary biliary cirrhosis is expected to be a major driver for growth of the primary biliary cirrhosis drugs market.
Market Dynamics- Drivers
Currently, only two U.S. Food and Drug Administration (FDA)-approved drugs, Ursodeoxycholic acid and Ocaliva, are available in market to reduce cirrhosis progression. However, large number of drugs are in pipeline, which is expected to propel growth of the global primary biliary cirrhosis drug market during the forecast period. For instance, in 2017, NGM Biopharmaceuticals, Inc. completed phase II clinical trials for its candidate drug NGM 282, an engineered variant of human hormone FGF19, to eliminate bile acid toxicity in primary biliary cirrhosis patients. NGM282 has a unique opportunity to leverage the dual targets of FGF19 without the potential non-tumorigenic property.
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Primary Biliary Cirrhosis Drugs Market Research Report: https://bit.ly/39gzRHP
Growing U.S. FDA-approvals for novel drugs is expected to drive the global primary biliary cirrhosis drug market growth in the near future. For instance, in 2016, Intercept Pharmaceuticals, Inc., received the U.S. FDA approval for its Ocaliva, obeticholic acid based drug, in combination with ursodeoxycholic acid for adults with inadequate response to ursodeoxycholic acid based monotherapy for the treatment of primary biliary cirrhosis. As on March 2018, University of Florida is investigating Fenofibrate Insoluble Drug Delivery – Micro Particle on patients with incomplete response to ursodeoxycholic acid. Moreover, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, is investigating Bezafibrate in combination with ursodeoxycholic acid for the treatment of primary biliary cirrhosis, which is in phase III clinical trials as on 2016. Furthermore, from the same source, it is estimated that 30 to 50% of patients with primary biliary cirrhosis shows partial response to ursodeoxycholic acid, which demands for combinational treatment. Janssen Research and Development also evaluated efficacy and safety of Ustekinumab for primary biliary cirrhosis with inadequate response to ursodeoxycholic acid. The research was in phase II clinical trial as of June 2016. These increasing pipeline products are expected to aid in growth of the primary biliary cirrhosis drugs market over the forecast period.
Furthermore, growing occurrence of primary biliary cirrhosis is expected to accelerate growth of the global primary biliary cirrhosis drugs market. Primary biliary cirrhosis occurs in patients aged 40–60 years and affects women more often than men. According to American Association for the Study of Liver Diseases (AASLD) published in 2016, prevalence of primary biliary cirrhosis (PBC) in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 persons. In UK, the prevalence of PBC is estimated to be 12.9 per 100,000 population, of which 90% of cases where reported in women. Furthermore, increasing incidence of autoimmune disease, tobacco smoking, tonsillectomy or urinary tract infection (in women) are risk factors, for primary biliary cirrhosis.
Based on geography, the primary biliary cirrhosis drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Among regions, North America holds dominant position in the global primary biliary cirrhosis drugs market. This is owing to increasing research and developmental activities by market players in the region. For instance, Enanta Pharmaceutical, Inc. is examining its EDP – 305, a potent FXR agonist for the treatment of primary biliary cirrhosis, which was in phase II clinical trials in 2017. However, Asia Pacific is expected to witness fastest growth in primary biliary cirrhosis drugs market due to high incidence of liver cirrhosis in the region. According to article published in 2014 of BMC medicine, mortality from liver cirrhosis was also comparatively high in Central Asia countries, particularly Mongolia, Uzbekistan and Kyrgyzstan.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/primary-biliary-cirrhosis-drugs-market-1539
Global Primary Biliary Cirrhosis Drugs Market – Competitor
Key players in the global primary biliary cirrhosis drugs market are Intercept Pharmaceuticals, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Dr. Falk Pharma GmbH, and Enanta Pharmaceuticals, Inc.
Global Primary Biliary Cirrhosis Drugs Market – Taxonomy
By Drug Type
- Ursodeoxycholic acid (USDA)
- Obeticholic acid
- Others (anti-inflamatory, anti-pruritics, and anti-histamines)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Table of Content
Global Primary Biliary Cirrhosis Drugs Market Research Report
Section 1: Global Primary Biliary Cirrhosis Drugs Industry Overview
Section 2: Global Economic Impact on Primary Biliary Cirrhosis Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Primary Biliary Cirrhosis Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Primary Biliary Cirrhosis Drugs Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire